Live-attenuated measles virus vaccine confers cell contact loss and apoptosis of ovarian cancer cells via ROS-induced silencing of E-cadherin by methylation.
Live-attenuated measles virus vaccine confers cell contact loss and apoptosis of ovarian cancer cells via ROS-induced silencing of E-cadherin by methylation.
复制标题
DOI:
10.1016/j.canlet.2011.10.038
复制
发表时间:
2012-05
期刊:
影响因子:
9.7
通讯作者:
Shengtao Zhou;Yuhua Li;Fuqiang Huang;Boya Zhang;T. Yi;Zhengyu Li;Hong Luo;Xiang He;Qian Zhong;C. Bian;Xiaojuan Lin;Xiaorong Qi;Ping Liu;Canhua Huang;Xia Zhao;Yuquan Wei
中科院分区:
文献类型:
--
作者:
Shengtao Zhou;Yuhua Li;Fuqiang Huang;Boya Zhang;T. Yi;Zhengyu Li;Hong Luo;Xiang He;Qian Zhong;C. Bian;Xiaojuan Lin;Xiaorong Qi;Ping Liu;Canhua Huang;Xia Zhao;Yuquan Wei
Herein we present a novel molecular mechanism of the antitumor effects of live-attenuated measles virus (MV) vaccine in ovarian cancer. Using a 2-DE/MS-based comparative proteomics strategy, we identified 17 proteins differentially expressed in live-attenuated MV vaccine-treated SKOV-3 ovarian cancer cells, including oxidative stress-associated enzymes and cell contact-related proteins, which indicated that live-attenuated MV vaccine could induce aberrant ROS activation. It further mediated epigenetic silencing of E-cadherin via upregulating DNMT3a that conferred both cell–cell and cell–matrix contact loss and apoptosis of ovarian cancer cells. This process could be reversed through ROS inhibition. Our study lays the theoretical foundation for the clinical application of live-attenuated MV vaccine as a potential oncotherapeutic agent for ovarian cancer treatment.